290 related articles for article (PubMed ID: 34606154)
1. Correction of oxidative stress enhances enzyme replacement therapy in Pompe disease.
Tarallo A; Damiano C; Strollo S; Minopoli N; Indrieri A; Polishchuk E; Zappa F; Nusco E; Fecarotta S; Porto C; Coletta M; Iacono R; Moracci M; Polishchuk R; Medina DL; Imbimbo P; Monti DM; De Matteis MA; Parenti G
EMBO Mol Med; 2021 Nov; 13(11):e14434. PubMed ID: 34606154
[TBL] [Abstract][Full Text] [Related]
2. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B
J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884
[TBL] [Abstract][Full Text] [Related]
3. Efficient therapy for refractory Pompe disease by mannose 6-phosphate analogue grafting on acid α-glucosidase.
Basile I; Da Silva A; El Cheikh K; Godefroy A; Daurat M; Harmois A; Perez M; Caillaud C; Charbonné HV; Pau B; Gary-Bobo M; Morère A; Garcia M; Maynadier M
J Control Release; 2018 Jan; 269():15-23. PubMed ID: 29108866
[TBL] [Abstract][Full Text] [Related]
4. Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice.
Zhu Y; Li X; McVie-Wylie A; Jiang C; Thurberg BL; Raben N; Mattaliano RJ; Cheng SH
Biochem J; 2005 Aug; 389(Pt 3):619-28. PubMed ID: 15839836
[TBL] [Abstract][Full Text] [Related]
5. The pharmacological chaperone AT2220 increases recombinant human acid α-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease.
Khanna R; Flanagan JJ; Feng J; Soska R; Frascella M; Pellegrino LJ; Lun Y; Guillen D; Lockhart DJ; Valenzano KJ
PLoS One; 2012; 7(7):e40776. PubMed ID: 22815812
[TBL] [Abstract][Full Text] [Related]
6. Conjugation of mannose 6-phosphate-containing oligosaccharides to acid alpha-glucosidase improves the clearance of glycogen in pompe mice.
Zhu Y; Li X; Kyazike J; Zhou Q; Thurberg BL; Raben N; Mattaliano RJ; Cheng SH
J Biol Chem; 2004 Nov; 279(48):50336-41. PubMed ID: 15383547
[TBL] [Abstract][Full Text] [Related]
7. Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease.
Peng J; Dalton J; Butt M; Tracy K; Kennedy D; Haroldsen P; Cahayag R; Zoog S; O'Neill CA; Tsuruda LS
J Pharmacol Exp Ther; 2017 Feb; 360(2):313-323. PubMed ID: 27856936
[TBL] [Abstract][Full Text] [Related]
8. A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease.
Han SO; Pope R; Li S; Kishnani PS; Steet R; Koeberl DD
Mol Genet Metab; 2016 Feb; 117(2):114-9. PubMed ID: 26454691
[TBL] [Abstract][Full Text] [Related]
9. Improved efficacy of a next-generation ERT in murine Pompe disease.
Xu S; Lun Y; Frascella M; Garcia A; Soska R; Nair A; Ponery AS; Schilling A; Feng J; Tuske S; Valle MCD; Martina JA; Ralston E; Gotschall R; Valenzano KJ; Puertollano R; Do HV; Raben N; Khanna R
JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30843882
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological enhancement of α-glucosidase by the allosteric chaperone N-acetylcysteine.
Porto C; Ferrara MC; Meli M; Acampora E; Avolio V; Rosa M; Cobucci-Ponzano B; Colombo G; Moracci M; Andria G; Parenti G
Mol Ther; 2012 Dec; 20(12):2201-11. PubMed ID: 22990675
[TBL] [Abstract][Full Text] [Related]
11. Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease.
Zhu Y; Jiang JL; Gumlaw NK; Zhang J; Bercury SD; Ziegler RJ; Lee K; Kudo M; Canfield WM; Edmunds T; Jiang C; Mattaliano RJ; Cheng SH
Mol Ther; 2009 Jun; 17(6):954-63. PubMed ID: 19277015
[TBL] [Abstract][Full Text] [Related]
12. Antibodies against recombinant human alpha-glucosidase do not seem to affect clinical outcome in childhood onset Pompe disease.
van Kooten HA; Ditters IAM; Hoogeveen-Westerveld M; Jacobs EH; van den Hout JMP; van Doorn PA; Pijnappel WWMP; van der Ploeg AT; van der Beek NAME
Orphanet J Rare Dis; 2022 Feb; 17(1):31. PubMed ID: 35109913
[TBL] [Abstract][Full Text] [Related]
13. β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.
Koeberl DD; Li S; Dai J; Thurberg BL; Bali D; Kishnani PS
Mol Genet Metab; 2012 Feb; 105(2):221-7. PubMed ID: 22154081
[TBL] [Abstract][Full Text] [Related]
14. Four unreported types of glycans containing mannose-6-phosphate are heterogeneously attached at three sites (including newly found Asn 233) to recombinant human acid alpha-glucosidase that is the only approved treatment for Pompe disease.
Park H; Kim J; Lee YK; Kim W; You SK; Do J; Jang Y; Oh DB; Il Kim J; Kim HH
Biochem Biophys Res Commun; 2018 Jan; 495(4):2418-2424. PubMed ID: 29274340
[TBL] [Abstract][Full Text] [Related]
15. Glycosylation-independent lysosomal targeting of acid α-glucosidase enhances muscle glycogen clearance in pompe mice.
Maga JA; Zhou J; Kambampati R; Peng S; Wang X; Bohnsack RN; Thomm A; Golata S; Tom P; Dahms NM; Byrne BJ; LeBowitz JH
J Biol Chem; 2013 Jan; 288(3):1428-38. PubMed ID: 23188827
[TBL] [Abstract][Full Text] [Related]
16. Production of recombinant human acid α-glucosidase with high-mannose glycans in gnt1 rice for the treatment of Pompe disease.
Jung JW; Huy NX; Kim HB; Kim NS; Van Giap D; Yang MS
J Biotechnol; 2017 May; 249():42-50. PubMed ID: 28363873
[TBL] [Abstract][Full Text] [Related]
17. Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease.
McVie-Wylie AJ; Lee KL; Qiu H; Jin X; Do H; Gotschall R; Thurberg BL; Rogers C; Raben N; O'Callaghan M; Canfield W; Andrews L; McPherson JM; Mattaliano RJ
Mol Genet Metab; 2008 Aug; 94(4):448-455. PubMed ID: 18538603
[TBL] [Abstract][Full Text] [Related]
18. Lipidic Nanoparticles Comprising Phosphatidylinositol Mitigate Immunogenicity and Improve Efficacy of Recombinant Human Acid Alpha-Glucosidase in a Murine Model of Pompe Disease.
Schneider JL; Dingman RK; Balu-Iyer SV
J Pharm Sci; 2018 Mar; 107(3):831-837. PubMed ID: 29102549
[TBL] [Abstract][Full Text] [Related]
19. Aggressive immunotherapy combined with bortezomib and rituximab for membranous nephropathy associated with enzyme replacement therapy in Pompe disease.
Sasaki K; Uchimura T; Inaba A; Otani M; Hanakawa J; Ito S
Pediatr Nephrol; 2023 Mar; 38(3):921-925. PubMed ID: 35864224
[TBL] [Abstract][Full Text] [Related]
20. A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease.
Byrne BJ; Geberhiwot T; Barshop BA; Barohn R; Hughes D; Bratkovic D; Desnuelle C; Laforet P; Mengel E; Roberts M; Haroldsen P; Reilley K; Jayaram K; Yang K; Walsh L;
Orphanet J Rare Dis; 2017 Aug; 12(1):144. PubMed ID: 28838325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
